Sabinsa Corporation’s founder Dr. Muhammed Majeed and his scientific staff have co-authored a booklet entitled "Boswellin® : Redefining Our Standards" to recommend that the supplement industry redefine its references to this ingredient.
In 1991, Sabinsa Corporation pioneered Boswellin® , a standardized extract containing boswellic acids, for the U.S. market. The prevalently used nomenclature for the anti-inflammatory constituents in Boswellia serrata extracts is "boswellic acids". Standardized extracts currently marketed are labeled as containing about 50% to70% boswellic acids. Isolation of the individual components and detailed analytical methodology, developed by Sabinsa Corporation, have now provided the necessary data to redefine this ingredient.
Change the phrase "boswellic acids" to "total organic acids" from Boswellia serrata.
This is applicable if you are using a 65-70% standardized organic acids raw material. The daily dose is to be 200 mg x 3 times, based on "total organic acids".
The term "pure boswellic acids" could also be used with the indication of the milligrams in each dosage form. The daily dose in this case will be approximately 50 mg x 3 times, based on four standardized "pure boswellic acids".
The booklet explains the science behind the proposed changes, and is available through Sabinsa Corporation, 70 Ethel Road West, Unit 6, Piscataway, NJ 08854 or 594 South American Way, Payson, Utah 84651.
Sabinsa Corporation which pioneered the introduction of several Ayurvedic herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, and the scientific credentials of its key technical staff.